Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03997643 · ClinicalTrials.gov registry record · Phase 2
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
A Phase 2 study of Head and Neck Cancer, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 8
- Study locations
NCT03997643 is a Phase 2 study of Head and Neck Cancer that is actively recruiting participants, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. The registered enrollment target is 90 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (65% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT03997643, a Phase 2 study of Head and Neck Cancer, is actively recruiting participants, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this randomized treatment study is to formally compare quality of life in patients with at least one pN0 hemi-neck after resection of a squamous cell carcinoma of the oral cavity treated with a primary radiation therapy versus a secondary targeted radiation therapy approach, to provide a high level of evidence to guide the selection of treatment options.
Conditions Studied
Interventions
- RADIATION Radiotherapy to all dissected areas
- RADIATION Omit radiation to pN0 neck
Study Locations (8)
Florida
- Miami Cancer Institute - Miami
Ontario
- London Regional Cancer Program - London
Quebec
- CHUM - Montreal
County Cork
- Cork University Hospital - Wilton
County Galway
- University Hospital Galway, Newcastle Road - Galway
Dublin
- St. Luke's Radiation Oncology Network - Rathgar
Leinster
- Beaumont St. Luke's Centre - Dublin
Other
- Beatson West of Scotland Cancer Centre - Glasgow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's1 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03997643
The ClinicalTrials.gov registry entry for NCT03997643 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (65% lower). The listed sponsor is London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiotherapy to all dissected areas is the first listed.
NCT03997643 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Florida, Ontario, Quebec.
Frequently Asked Questions
What is clinical trial NCT03997643 about?
NCT03997643 is a clinical study titled "Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial". The goal of this randomized treatment study is to formally compare quality of life in patients with at least one pN0 hemi-neck after resection of a squamous cell carcinoma of the oral cavity treated with a primary radiation therapy versus a secondary targeted radiation therapy approach, to provide a...
What is the current status of trial NCT03997643?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2019-09-06. Estimated completion is 2026-09.
What conditions does trial NCT03997643 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT03997643?
The interventions under investigation include: Radiotherapy to all dissected areas (RADIATION), Omit radiation to pN0 neck (RADIATION).
Who is sponsoring clinical trial NCT03997643?
This trial is sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03997643 being conducted?
This trial has 8 study locations across Florida, Ontario, Quebec, County Cork, County Galway. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.